Anthony Esposito, Jr. Joins InClinica as Senior Director of Quality Assurance
PHILADELPHIA (July 12, 2018) – InClinica, a global clinical CRO, announced today that Anthony J. Esposito, Jr. has been appointed Senior Director of Quality Assurance. In his new role, Esposito will be responsible for establishing and executing all quality processes and strategies across the company.
“We are very excited to welcome Anthony to the team,” said James Nolan, CEO at InClinica. “His decades of experience in global quality assurance will greatly benefit InClinica’s clinical trial operations, and how they perform and comply with inspections globally.”
Esposito has more than 25 years of experience in the pharmaceutical industry, specifically in global quality assurance and clinical operations. Prior to joining InClinica, Esposito spent 16 years with Janssen Pharmaceutical Research & Development, LLC, where he most recently served as Regional Therapeutic Area Expert. He was responsible for establishing immunology strategies for North and South America, providing direction for successful trial execution, optimizing protocol design and defining efficient regional commitment for the trial. The majority of his career at Janssen was as the Global Quality Assurance lead for the Immunology franchise.
In addition, Esposito has extensive experience in therapeutic areas including immunology, oncology, dermatology, metabolism, CNS, CV, neuroscience and stem cells.
He received his bachelor’s degree in English and Psychology, with a concentration in sciences, from Rutgers University.
InClinica is a global clinical contract research organization founded in 2016 after the acquisition of an existing global CRO. With a senior management team that brings more than 100 combined years of experience, InClinica works across all phases of the clinical research process and has a particular strength in first in man and phase 2 studies. InClinica is headquartered in Philadelphia with other locations in the U.K., Israel, and Malaysia/Singapore.